AHU-377 hemicalcium salt, also known as sacubitril calcium salt, is a neprilysin inhibitor primarily used in the development of pharmaceutical compounds for the treatment of cardiovascular diseases. It is the active pharmaceutical ingredient in sacubitril, a key component of the combination drug sacubitril/valsartan (Entresto), which is widely prescribed for managing chronic heart failure with reduced ejection fraction and hypertension. By inhibiting neprilysin, AHU-377 hemicalcium salt enhances the levels of beneficial peptides, such as natriuretic peptides (e.g., ANP and BNP), that promote vasodilation, reduce sodium retention, diuresis, and improve overall cardiac function. Its role in this therapeutic application underscores its importance as a specialty chemical intermediate in advancing treatments for heart failure and improving patient outcomes.